SG11201704519YA - Methods and compositons for treating cancer - Google Patents
Methods and compositons for treating cancerInfo
- Publication number
- SG11201704519YA SG11201704519YA SG11201704519YA SG11201704519YA SG11201704519YA SG 11201704519Y A SG11201704519Y A SG 11201704519YA SG 11201704519Y A SG11201704519Y A SG 11201704519YA SG 11201704519Y A SG11201704519Y A SG 11201704519YA SG 11201704519Y A SG11201704519Y A SG 11201704519YA
- Authority
- SG
- Singapore
- Prior art keywords
- compositons
- methods
- treating cancer
- cancer
- treating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086346P | 2014-12-02 | 2014-12-02 | |
| PCT/US2015/063267 WO2016089916A1 (en) | 2014-12-02 | 2015-12-01 | Methods and compositons for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704519YA true SG11201704519YA (en) | 2017-07-28 |
Family
ID=56078487
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704519YA SG11201704519YA (en) | 2014-12-02 | 2015-12-01 | Methods and compositons for treating cancer |
| SG10202103475XA SG10202103475XA (en) | 2014-12-02 | 2015-12-01 | Methods and compositons for treating cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202103475XA SG10202103475XA (en) | 2014-12-02 | 2015-12-01 | Methods and compositons for treating cancer |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9650428B2 (OSRAM) |
| EP (1) | EP3227317A4 (OSRAM) |
| JP (1) | JP2017537622A (OSRAM) |
| KR (1) | KR20180041087A (OSRAM) |
| CN (1) | CN107709353A (OSRAM) |
| AR (1) | AR102879A1 (OSRAM) |
| AU (1) | AU2015355084A1 (OSRAM) |
| BR (1) | BR112017011771A2 (OSRAM) |
| CA (1) | CA2969714A1 (OSRAM) |
| EA (1) | EA201791210A1 (OSRAM) |
| HK (1) | HK1251862A1 (OSRAM) |
| IL (1) | IL252610A0 (OSRAM) |
| MX (1) | MX2017007272A (OSRAM) |
| PH (1) | PH12017501031A1 (OSRAM) |
| SG (2) | SG11201704519YA (OSRAM) |
| TW (1) | TW201636425A (OSRAM) |
| UY (1) | UY36418A (OSRAM) |
| WO (1) | WO2016089916A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013112871A1 (en) | 2012-01-27 | 2013-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic il-13 polypeptides |
| JP6445434B2 (ja) | 2012-08-09 | 2018-12-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | スーパーカインおよびシンセカイン：新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン |
| ES2949648T3 (es) | 2012-12-20 | 2023-10-02 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| BR112017011771A2 (pt) | 2014-12-02 | 2018-07-10 | Prospect Chartercare Rwmc Llc | métodos e composições para o tratamento de câncer |
| FI3909972T3 (fi) * | 2015-06-19 | 2024-05-03 | Sebastian Kobold | Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä |
| WO2017023138A1 (ko) * | 2015-08-05 | 2017-02-09 | 주식회사 유영제약 | 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| US20200095301A1 (en) * | 2016-12-14 | 2020-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13 superkine: immune cell targeting constructs and methods of use thereof |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| CN110753555A (zh) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| WO2019073299A1 (en) | 2017-10-10 | 2019-04-18 | Medicenna Therapeutics, Inc. | IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS |
| WO2019100079A1 (en) * | 2017-11-20 | 2019-05-23 | Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center | Compositions for improving car-t cell functionality and user thereof |
| EP3728305A1 (en) | 2017-12-20 | 2020-10-28 | Poseida Therapeutics, Inc. | Vcar compositions and methods for use |
| BR112020014913A2 (pt) | 2018-01-22 | 2020-12-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Métodos para uso de células t car |
| EP3743445A1 (en) * | 2018-01-26 | 2020-12-02 | City of Hope | Chimeric antigen receptors and methods for reducing off target toxicity |
| SG11202007426XA (en) | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CN110157674A (zh) * | 2018-02-12 | 2019-08-23 | 深圳宾德生物技术有限公司 | 一种靶向性t淋巴细胞及其制备方法和应用 |
| CN110144326A (zh) * | 2018-02-12 | 2019-08-20 | 深圳宾德生物技术有限公司 | 一种靶向性抗肿瘤t细胞及其制备方法和应用 |
| CN111918661A (zh) | 2018-02-21 | 2020-11-10 | 得克萨斯大学体系董事会 | 用于活化和扩增自然杀伤细胞的方法及其用途 |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| CN108440674A (zh) * | 2018-04-28 | 2018-08-24 | 杭州荣泽生物科技有限公司 | 一种Trop-2特异性嵌合抗原受体细胞制备及其用途 |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| US12419954B2 (en) * | 2020-01-31 | 2025-09-23 | City Of Hope | Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies |
| EP4159237A4 (en) * | 2020-05-28 | 2024-08-28 | Chugai Seiyaku Kabushiki Kaisha | Improved granzyme b variant |
| WO2022046938A1 (en) * | 2020-08-26 | 2022-03-03 | The Regents Of The University Of California | Methods and compositions for treating glioblastoma |
| BR112023004433A2 (pt) * | 2020-09-11 | 2023-04-11 | Univ Georgia | Ácido nucleico, vetor, segmento genômico viral, vírus, composição farmacêutica, método para induzir ou aumentar uma resposta imune contra o vírus influenza, vírus recombinante, método para induzir uma resposta imune em um sujeito em necessidade e polipeptídeo |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN114907485B (zh) * | 2021-02-08 | 2024-04-26 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| CN113304267B (zh) * | 2021-06-11 | 2022-03-15 | 河南大学 | 肺癌的治疗靶点及其应用 |
| CN114014941B (zh) * | 2022-01-10 | 2022-04-12 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
| CN116549667B (zh) * | 2023-05-29 | 2024-02-09 | 四川普锐特药业有限公司 | 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965126A (en) * | 1996-03-25 | 1999-10-12 | The Penn State Research Foundation | use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents |
| ATE392479T1 (de) * | 1999-10-20 | 2008-05-15 | Univ Johns Hopkins Med | Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure |
| MXPA04008408A (es) * | 2002-03-01 | 2004-11-29 | Squibb Bristol Myers Co | Mamiferos no humanos, transgenicos, que expresan receptores de la tirosina cinasa activados constitutivamente. |
| WO2003086451A1 (en) * | 2002-04-05 | 2003-10-23 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| US7709625B2 (en) * | 2004-06-10 | 2010-05-04 | The Board Of Regents Of The University Of Texas | Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy |
| CA2630334C (en) * | 2005-11-16 | 2013-07-23 | Universidad Nacional Autonoma De Mexico | Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer |
| CN101616685B (zh) * | 2006-03-06 | 2013-07-24 | 阿穆尼克斯运营公司 | 非结构化重组聚合物和其应用 |
| US20080206139A1 (en) * | 2006-11-03 | 2008-08-28 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| CA2735456C (en) * | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| HUE032519T2 (en) * | 2010-03-26 | 2017-09-28 | Memorial Sloan Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
| EP2931893A1 (en) * | 2012-12-13 | 2015-10-21 | Universität Leipzig | T-cell modulation by exon skipping |
| KR102064230B1 (ko) * | 2013-02-15 | 2020-01-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| WO2014164554A1 (en) * | 2013-03-10 | 2014-10-09 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| ES2792849T3 (es) * | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| BR112017011771A2 (pt) | 2014-12-02 | 2018-07-10 | Prospect Chartercare Rwmc Llc | métodos e composições para o tratamento de câncer |
-
2015
- 2015-12-01 BR BR112017011771A patent/BR112017011771A2/pt not_active Application Discontinuation
- 2015-12-01 SG SG11201704519YA patent/SG11201704519YA/en unknown
- 2015-12-01 CN CN201580074883.3A patent/CN107709353A/zh active Pending
- 2015-12-01 EA EA201791210A patent/EA201791210A1/ru unknown
- 2015-12-01 HK HK18110565.4A patent/HK1251862A1/zh unknown
- 2015-12-01 AU AU2015355084A patent/AU2015355084A1/en not_active Abandoned
- 2015-12-01 US US14/956,299 patent/US9650428B2/en not_active Expired - Fee Related
- 2015-12-01 WO PCT/US2015/063267 patent/WO2016089916A1/en not_active Ceased
- 2015-12-01 KR KR1020177018139A patent/KR20180041087A/ko not_active Withdrawn
- 2015-12-01 JP JP2017529284A patent/JP2017537622A/ja active Pending
- 2015-12-01 SG SG10202103475XA patent/SG10202103475XA/en unknown
- 2015-12-01 MX MX2017007272A patent/MX2017007272A/es unknown
- 2015-12-01 EP EP15865800.5A patent/EP3227317A4/en not_active Withdrawn
- 2015-12-01 CA CA2969714A patent/CA2969714A1/en not_active Abandoned
- 2015-12-02 UY UY0001036418A patent/UY36418A/es not_active Application Discontinuation
- 2015-12-02 TW TW104140317A patent/TW201636425A/zh unknown
- 2015-12-02 AR ARP150103939A patent/AR102879A1/es unknown
-
2017
- 2017-05-09 US US15/590,961 patent/US20180072789A1/en not_active Abandoned
- 2017-06-01 IL IL252610A patent/IL252610A0/en unknown
- 2017-06-02 PH PH12017501031A patent/PH12017501031A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1251862A1 (zh) | 2019-04-26 |
| TW201636425A (zh) | 2016-10-16 |
| BR112017011771A2 (pt) | 2018-07-10 |
| EA201791210A1 (ru) | 2017-11-30 |
| CN107709353A (zh) | 2018-02-16 |
| EP3227317A1 (en) | 2017-10-11 |
| IL252610A0 (en) | 2017-07-31 |
| CA2969714A1 (en) | 2016-06-09 |
| UY36418A (es) | 2016-06-30 |
| US20180072789A1 (en) | 2018-03-15 |
| AR102879A1 (es) | 2017-03-29 |
| KR20180041087A (ko) | 2018-04-23 |
| PH12017501031A1 (en) | 2017-11-27 |
| SG10202103475XA (en) | 2021-05-28 |
| US20160151490A1 (en) | 2016-06-02 |
| JP2017537622A (ja) | 2017-12-21 |
| US9650428B2 (en) | 2017-05-16 |
| WO2016089916A1 (en) | 2016-06-09 |
| EP3227317A4 (en) | 2018-04-25 |
| AU2015355084A1 (en) | 2017-06-29 |
| MX2017007272A (es) | 2018-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304820A (en) | Preparations and methods for the treatment of cancer | |
| IL323396A (en) | Cancer treatment methods | |
| IL252610A0 (en) | Methods and preparations for the treatment of cancer | |
| IL289947A (en) | A method for treating cancer | |
| IL267247B (en) | Compositions and methods for treating cancer | |
| IL266053A (en) | Preparations and methods for the treatment of ezh2-mediated cancer | |
| ZA201804227B (en) | Methods of treating cancer | |
| IL255189A0 (en) | Cancer treatment methods | |
| EP3177292A4 (en) | Compounds and methods for treating cancer | |
| SMT202100273T1 (it) | Metodi e composizioni per il trattamento del cancro | |
| IL256836B (en) | Methods for treating cancer using apilimod | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| IL255022A0 (en) | Cancer treatment methods | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| IL247859A0 (en) | Cancer treatment | |
| IL246558A0 (en) | New methods of cancer treatment | |
| IL255018A0 (en) | Cancer treatment methods | |
| SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
| IL255016A0 (en) | Cancer treatment methods | |
| IL256763A (en) | Compositions and methods for treating cancer | |
| EP3160591A4 (en) | Compositions and methods for treating cancer | |
| GB201414904D0 (en) | Materials and methods for treating cancer | |
| GB201418640D0 (en) | Agents and methods for treatment of cancer |